Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Clinical Genetics and Genomics, |
RCV001269867 | SCV001450184 | pathogenic | not provided | 2016-07-14 | criteria provided, single submitter | clinical testing | |
Mendelics | RCV002246266 | SCV002517641 | pathogenic | Endometrial carcinoma | 2022-05-04 | criteria provided, single submitter | clinical testing | |
Laboratory for Molecular Medicine, |
RCV004017816 | SCV004848352 | likely pathogenic | Lynch syndrome | 2020-05-13 | criteria provided, single submitter | clinical testing | The p.Asn1065LysfsX5 variant in MSH6 has been reported in an individual with Lynch syndrome (Sjursen 2010) and was absent from large population studies. This variant has also been reported in ClinVar (Variation ID 89350). This variant is predicted to cause a frameshift, which alters the protein’s amino acid sequence beginning at position 1065 and leads to a premature termination codon five amino acids downstream. This alteration is then predicted to lead to a truncated or absent protein. Loss of function of the MSH6 gene is an established disease mechanism in autosomal dominant Lynch syndrome. In summary, although additional studies are required to fully establish its clinical significance, this variant meets criteria to be classified as likely pathogenic for autosomal dominant Lynch syndrome. ACMG/AMP Criteria applied: PVS1, PM2 |